Therapeutic efficacy of moxifloxacin in a murine model of severe systemic mixed infection with Escherichia coli and Bacteroides fragilis

Anaerobe

Volumn 9, Issue 4, 2003, Pages 157-160

  Eckhardt, Christiane ^a   Fickweiler, Kristina ^a   Schaumann, Reiner ^a   Ackermann, Grit ^a   Rodloff, Arne C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

B. fragilis; E. coli; Mixed infection; Moxifloxacin; Therapy

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN PLUS IMIPENEM; CIPROFLOXACIN PLUS METRONIDAZOLE; MOXIFLOXACIN; UNCLASSIFIED DRUG;

ANAEROBIC INFECTION; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEASIBILITY STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; BACTERIA (MICROORGANISMS); BACTEROIDES; BACTEROIDES FRAGILIS; ESCHERICHIA COLI; MURINAE;

EID: 0141453451     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1075-9964(03)00086-6     Document Type: Article

References (20)

1. Dalhoff A., Peterson U., Endermann R. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy. 42:1996;410-425.
2. Ackermann G., Schaumann R., Pless B., Claros M.C., Goldstein E.J.C., Rodloff A.C. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 19:2000;228-232.
3. Bauernfeind A. Comparison of the antimicrobial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 40:1997;639-651.
4. Woodcock J.M., Andrews J.M., Boswell F.J., Brenwald N.P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinilone. Antimicrob Agents Chemother. 41(1):1997;101-106.
5. Kleinkauf N., Ackermann G., Schaumann R., Rodloff A.C. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother. 45(6):2001;1896-1899.
6. Horn R., Robson H.G. Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. J Antimicrob Chemother. 48:2001;127-130.
7. Nightingale C.M. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections. a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics Pharmacotherapy. 20(3):2000;245-256.
8. Rodloff A.C., Rodloff S., Fischer B., Hahn H. Intravenous infection of mice with Bacteroides fragilis and Escherichia coli. role of thioglycollate medium in the infectious process Zentralbl Bakteriol Mikrobiol Hyg [A]. 254:1983;405-412.
9. Wilson S.E. Carbapenems: monotherapy in intra-abdominal sepsis. Scand J Infect Dis. 96:1995;28-33.
10. Solomkin J.S., Reinhardt H.H., Dellinger E.P., Bohnen J.M., Rotstein O.D., Vogel S.B., et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazol to imipenem/cilastatin for intra-abdominal infection. The intra-abdominal infection study group. Ann Surg. 223:1996;303-315.
11. Nathens A.B., Rotstein O.D. Antimicrobial therapy for intra-abdominal infection. Am J Surg. 172(Suppl 6A):1996;1-6.
12. Medizinische Mikrobiologie und Immunologie: Normen und weitere Unterlagen. DIN. Berlin, Germany: Deutsches Institut für Normung e. V., Beuth Verlag GmbH; 1999.
13. Löscher W., Ungemach F.R., Kroker R. Pharmakotherapie bei Haus- und Nutztieren. 4th ed:1999;Parey, Berlin, Germany.
14. Rodloff A.C., Fischer B., Görtz G., Raetzel H., Hahn H. Efficacy of gentamycin, metronidazole, and latamoxef in the treatment of mice infected with Escherichia coli and Bacteroides fragilis. Antimikrob Antineopl Chemother. 2:1984;153-160.
15. Onderdonk A.B., Kasper D.L., Cisneros R.L., Bartlett G.J. The capsular polysaccharide of Bacteroides fragilis as a virulence factor. comparison of the pathogenic potential of encapsulated and unencapsulated strains J Infect Dis. 136:1977;82-89.
16. Kasper D.L., Onderdonk A.B., Crabb J., Bartlett G.J. Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis. J Infect Dis. 140:1979;724-731.
17. Thadepalli H., Reddy U., Chuah S.K., Thadepalli F., Malilay C., Polzer R.J., et al. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 41:1997;583-586.
18. Cisneros R, Onderdonk AB. Therapeutic efficacy of BMS 284756 for the treatment of intraabdominal sepsis (IAS). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Washington, DC: American Society for Microbiology; 2000. p. 55 [Abstract 966].
19. Lahnborg G., Nord C.E. Effect of ciprofloxacin compared to gentamicin in the treatment of experimental intraabdominal infection in rats. Scand J Infect Dis. 60:1989;35-38.
20. Brook I., Gilmore J.D. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice. J Antimicrob Chemother. 31:1993;393-401.